Survival analysis of patients with medium and advanced hepatocellular carcinoma treated by TACE combined with Endostar

• Main Authors: Xiu-Heng Qi, Zhen-Ming Wu, Qi Liu, Qian Guo, Ling-Ling Wang, Shuai-Bing Wang
• Format: Article
• Language: English
• Published: SAGE Publishing 2020-10-01
• Series: European Journal of Inflammation
• Online Access: https://doi.org/10.1177/2058739220960552

To explore the effects of two different administration routes of Endostar on the survival of patients with medium and advanced hepatocellular carcinoma (HCC) and underwent trans-arterial chemoembolization (TACE). Seventy-two patients with medium and advanced HCC were enrolled. Among them, 42 patients underwent the hepatic arterial infusion of Endostar combined with TACE (infusion therapy group); and the remaining 30 patients underwent the hepatic treatment of TACE combined with the intravenous application of Endostar (intravenous therapy group). All patients underwent regular examinations of CT (or MRI) and DSA to observe the conditions of tumor recurrence or metastasis, and to determine the existence of tumor angiogenesis. The response rate of treatment in the Endostar hepatic arterial infusion group was higher than that in the control group, and the difference was statistically significant (31/42:14/30, X 2  = 5.501, p  < 0.05). In addition, median progression free-survival time of the two groups were 8.67 months and 6.67 months, respectively ( p  = 0.046); and the difference was statistically significant. The hepatic arterial infusion of Endostar combined with TACE can significantly improve recent clinical efficacy and mPFS in the treatment of medium and advanced HCC. However, improvement on the overall survival of long-term efficacy is not significant.